Facemask Testing

One of the main factors influencing the amount of inhaled drug available to the patient is the interface between the facemask and the patient. Investigating and defining the effect of a facemask to the product’s DDU and APSD is important for the product development.

Spacers/VHCs
Nebulisers
Spacers/VHCs
Nebulisers

Please select an option:

DDU APSD
View Brochure

Please select an option:

DDU APSD
View Brochure

Related Services

Training

Training

We offer a range of training courses, presentations and seminars covering a wide range of topics.

Find Out More
Training

Servicing

A comprehensive range of both in-house and on-site product servicing options are available

Find Out More
Training

Support

Our team of experienced technicians and engineers are on hand to help and advise

Find Out More

Related News & Resources

Introducing the Copley Impactor Genie™ IG 200i, a two-in-one solution for quicker, more efficient inhaled product testing

25th April 2023

Find out more

Copley Scientific joins the Industries Forum of the Taskforce for Lung Health

22nd June 2021

Find out more

Introducing Inhalytix®: a new solution for analysing and managing inhaler test data from Copley

18th March 2021

Find out more

Copley announces a major upgrade of the world’s ‘go to’ inhaler testing portfolio

1st March 2021

Find out more

New e-Training service from Copley for pharmaceutical testing

29th January 2021

Find out more

Copley Scientific releases new accessories for testing nebulisers with facemasks

31st May 2018

Find out more

Copley Scientific previews new apparatus for metered dose inhaler testing at DDL 25

11th November 2014

Find out more

PMPS Q&A (Samedan): April 2021

View download

Microbioz India: February 2021

View download

Drug Development & Delivery Article: April 2018

View download

PMPS Article (Samedan): February 2018

View download

White Paper: February 2018

View download

American Pharmaceutical Review Article: Nov/Dec 2017

View download